4142:TPE
Adimmune Corp
15,85Â TWD
arrow_downward
−1,86%(−0,30) 1 pv
19.11., 13.30.08 UTC+8 · TWD
search
Kaikki symbolit
| Symboli | Hinta | Muutos | Muutos (%) |
|---|
insights_autoLuodaan huippuvinkkejä: 4142…
Avaa
16,20Â TWD
Korkea
16,25Â TWD
Matala
15,70Â TWD
Markkina-arvo
6,81Â mrd.
Keskimääräinen volyymi
1,09Â milj.
Volyymi
1,60Â milj.
P/E-luku
91,85
52 viikon ylin
21,50Â TWD
52 viikon alin
15,65Â TWD
Osakekohtainen tulos (EPS)
0,17Â TWD
Liikkeellä olevat osakkeet
235,29Â milj.
Työntekijöiden lukumäärä
564
Avaa
16,20Â TWD
Korkea
16,25Â TWD
Matala
15,70Â TWD
Markkina-arvo
6,81Â mrd.
Keskimääräinen volyymi
1,09Â milj.
Volyymi
1,60Â milj.
P/E-luku
91,85
52 viikon ylin
21,50Â TWD
52 viikon alin
15,65Â TWD
Osakekohtainen tulos (EPS)
0,17Â TWD
Liikkeellä olevat osakkeet
235,29Â milj.
Työntekijöiden lukumäärä
564
Uutiset
Verkkolähteistä ja uutiskumppaneilta
Yahoo Finance
·
2 tuntia sitten
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
MarketWatch
·
14 minuuttia sitten
Stock Market Today: Nasdaq to lead Dow and S&P 500 higher as tech rallies on Anthropic IPO optimism; Nvidia stock gains; Walmart earnings on tap: live updates
Los Angeles Times
·
15 tuntia sitten
A fifth straight drop for the S&P 500 drags Wall Street to its longest losing streak since June
The Motley Fool
·
15 tuntia sitten
ExxonMobil (XOM) Just Achieved Something 95% of S&P 500 (GSPC) Members Haven't Done
Profiili
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Tietoa: Adimmune Corp
Toimitusjohtaja-
Työntekijät564
Perustamispäivä1965
Päätoimipaikka-
ToimialaHealth Care
Toimiala-
Sivustoadimmune.com.tw